Exane Derivatives Blueprint Medicines Corp Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Exane Derivatives holds 8 shares of BPMC stock, worth $811. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8
Previous 567
98.59%
Holding current value
$811
Previous $36,000
100.0%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding BPMC
# of Institutions
339Shares Held
61.9MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$674 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$663 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$596 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$328 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$249 Million8.22% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $6.05B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...